{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T16:11:58Z","timestamp":1764259918258},"reference-count":33,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.leukres.2015.03.014","type":"journal-article","created":{"date-parts":[[2015,4,6]],"date-time":"2015-04-06T04:13:43Z","timestamp":1428293623000},"page":"592-598","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Anagrelide treatment and cardiovascular monitoring in essential thrombocythemia. A prospective observational study"],"prefix":"10.1016","volume":"39","author":[{"given":"Giovanni","family":"Tortorella","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Piccin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Tieghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Marcheselli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Steurer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fcnther","family":"Gastl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katia","family":"Codeluppi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Fama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umberto","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Birtolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Gugliotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Cortelazzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Gugliotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2015.03.014_bib0170","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/sj.leu.2404955","article-title":"Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2015.03.014_bib0175","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.1990.8.3.556","article-title":"Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia","volume":"8","author":"Cortelazzo","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2015.03.014_bib0180","first-page":"215","article-title":"Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation","volume":"89","author":"Barbui","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2015.03.014_bib0185","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1055\/s-2006-942758","article-title":"Risk factors for thrombosis and bleeding and their influence on therapeutic decisions in patients with essential thrombocythemia","volume":"32","author":"Griesshammer","year":"2006","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.leukres.2015.03.014_bib0190","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2141.2010.08122.x","article-title":"Guideline for investigation and management of adults and children presenting with a thrombocytosis","volume":"149","author":"Harrison","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2015.03.014_bib0195","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2015.03.014_bib0200","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1182\/blood-2012-01-403279","article-title":"A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment","volume":"120","author":"Passamonti","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.03.014_bib0205","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","article-title":"Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)","volume":"120","author":"Barbui","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.03.014_bib0210","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1365-2141.1993.tb08272.x","article-title":"Vascular complications of essential thrombocythaemia: a link to cardiovascular risk factors","volume":"83","author":"Watson","year":"1993","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2015.03.014_bib0215","first-page":"390","article-title":"Prior thrombosis and clinico-biological characteristics at diagnosis in the patients of the Thrombocythemias Italian Registry: is older age a primary or a surrogate pro-thrombotic factor?","volume":"99","author":"Gugliotta","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2015.03.014_bib0220","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1046\/j.1365-2796.1998.00314.x","article-title":"Acute coronary disease in essential thrombocythemia and polycythemia vera","volume":"244","author":"Rossi","year":"1998","journal-title":"J Intern Med"},{"key":"10.1016\/j.leukres.2015.03.014_bib0225","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/sj.leu.2401270","article-title":"Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients","volume":"13","author":"Besses","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2015.03.014_bib0230","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1378\/chest.99.3.557","article-title":"Cardiotoxicity of interferon. A review of 44 cases","volume":"99","author":"Sonnenblick","year":"1991","journal-title":"Chest"},{"key":"10.1016\/j.leukres.2015.03.014_bib0235","series-title":"Summary of Product Characteristics for Roferon-A","author":"Roche","year":"2008"},{"key":"10.1016\/j.leukres.2015.03.014_bib0240","series-title":"Summary of Product Characteristics for Pegasys","author":"Roche","year":"2009"},{"key":"10.1016\/j.leukres.2015.03.014_bib0245","series-title":"Summary of Product Characteristics for Intron-A","author":"Schering-Plough","year":"2009"},{"key":"10.1016\/j.leukres.2015.03.014_bib0250","series-title":"Summary of Product Characteristics for Xagrid","author":"Shire","year":"2011"},{"key":"10.1016\/j.leukres.2015.03.014_bib0255","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0002-9343(92)90017-6","article-title":"A therapy for thrombocythemic states: experience in 577 patients. Anagrelide Study Group","volume":"92","author":"Anagrelide","year":"1992","journal-title":"Am J Med"},{"key":"10.1016\/j.leukres.2015.03.014_bib0260","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1517\/14656566.1.3.537","article-title":"Anagrelide: a novel agent for the treatment of myeloproliferative disorders","volume":"1","author":"Pescatore","year":"2000","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.leukres.2015.03.014_bib0265","first-page":"921","article-title":"Anagrelide in essential thrombocythemia: a retrospective analysis of 220 patients","volume":"102","author":"Gugliotta","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.03.014_bib0270","first-page":"1306","article-title":"A long-term study of young patients with essential thrombocythemia treated with anagrelide","volume":"89","author":"Mazzucconi","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2015.03.014_bib0275","first-page":"520","article-title":"Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders","volume":"89","author":"Birgegard","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2015.03.014_bib0280","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.leukres.2004.10.002","article-title":"Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders","volume":"29","author":"Fruchtman","year":"2005","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2015.03.014_bib0285","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2015.03.014_bib0290","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1586\/14737140.9.1.37","article-title":"Anagrelide: 20 years later","volume":"9","author":"Emadi","year":"2009","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.leukres.2015.03.014_bib0295","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.medcli.2009.03.024","article-title":"Retrospective analysis of the efficacy and tolerability of anagrelide in patients with essential thrombocytemia: Spanish registry of essential thrombocytemia","volume":"133","author":"Giralt","year":"2009","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.leukres.2015.03.014_bib0300","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood-2012-07-443770","article-title":"Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial","volume":"121","author":"Gisslinger","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.03.014_bib0305","article-title":"Monitoring safety outcomes in at-risk essential thrombocythemia patients treated with anagrelide vs other cytoreductive therapies: the Evaluation of Xagrid Efficacy and Long-term Safety (EXELS) study","author":"Birgegard","year":"2009","journal-title":"Abstract ICMPMDS"},{"key":"10.1016\/j.leukres.2015.03.014_bib0310","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.leukres.2011.06.030","article-title":"Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia","volume":"35","author":"Gugliotta","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2015.03.014_bib0315","first-page":"94","article-title":"Anagrelide e inibitori delle fosfodiesterasi","volume":"2","author":"Tortorella","year":"2009","journal-title":"Cardiol. Ambul"},{"key":"10.1016\/j.leukres.2015.03.014_bib0320","first-page":"6","article-title":"How to manage palpitations when treating ET","volume":"3","author":"Martinez-Selles","year":"2009","journal-title":"Myeloproliferative Disord Pract"},{"key":"10.1016\/j.leukres.2015.03.014_bib0325","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.leukres.2011.07.031","article-title":"Anagrelide and cardiovascular events. Much ado about nothing?","volume":"35","author":"Besses","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2015.03.014_bib0330","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s40261-012-0032-2","article-title":"Cardiovascular safety of anagrelide in healthy subjects: effects of caffeine and food intake on pharmacokinetics and adverse reactions","volume":"33","author":"Martinez-Selles","year":"2013","journal-title":"Clin Drug Investig"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212615000843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212615000843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,23]],"date-time":"2018-09-23T21:50:18Z","timestamp":1537739418000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212615000843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S0145212615000843"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2015.03.014","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anagrelide treatment and cardiovascular monitoring in essential thrombocythemia. A prospective observational study","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2015.03.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}